{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:51:17Z","timestamp":1791312677306,"version":"4.3.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":128,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2024M750127"],"award-info":[{"award-number":["2024M750127"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81872083, 81972379, and 82173216"],"award-info":[{"award-number":["81872083, 81972379, and 82173216"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"DOI":"10.1186\/s12916-026-04961-2","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T06:42:52Z","timestamp":1780123372000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cytoreductive radical prostatectomy in patients with high-volume metastatic prostate cancer achieving deep biochemical response to contemporary systemic therapy: a multicentre, prospective cohort study"],"prefix":"10.1186","volume":"24","author":[{"given":"Cong","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenzhi","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingrui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangjie","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Rui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiming","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanjie","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuesong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,30]]},"reference":[{"issue":"3","key":"4961_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"4961_CR2","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1200\/JCO.20.03256","volume":"39","author":"KS Virgo","year":"2021","unstructured":"Virgo KS, Rumble RB, de Wit R, Mendelson DS, Smith TJ, Taplin ME, et al. Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update. J Clin Oncol. 2021;39(11):1274\u2013305.","journal-title":"J Clin Oncol"},{"issue":"6","key":"4961_CR3","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1097\/JU.0000000000003452","volume":"209","author":"W Lowrance","year":"2023","unstructured":"Lowrance W, Dreicer R, Jarrard DF, Scarpato KR, Kim SK, Kirkby E, et al. Updates to Advanced Prostate Cancer: AUA\/SUO Guideline (2023). J Urol. 2023;209(6):1082\u201390.","journal-title":"J Urol"},{"issue":"8","key":"4961_CR4","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1200\/OP-24-00690","volume":"21","author":"AD Raval","year":"2025","unstructured":"Raval AD, Lunacsek O, Korn MJ, Littleton N, Constantinovici N, George DJ. Real-World Evidence of Combination Therapy Use in Metastatic Hormone-Sensitive Prostate Cancer in the United States From 2017 to 2023. JCO Oncol Pract. 2025;21(8):1174\u201384.","journal-title":"JCO Oncol Pract"},{"key":"4961_CR5","doi-asserted-by":"crossref","unstructured":"May M, Gilfrich C, Enzinger B, Brookman-May S. Exercise oncology in prostate cancer: from observational insight to prescriptive precision. Br J Cancer. 2025.","DOI":"10.1038\/s41416-025-03205-z"},{"issue":"10162","key":"4961_CR6","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","volume":"392","author":"CC Parker","year":"2018","unstructured":"Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet. 2018;392(10162):2353\u201366.","journal-title":"Lancet"},{"issue":"3","key":"4961_CR7","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.eururo.2018.09.008","volume":"75","author":"LMS Boeve","year":"2019","unstructured":"Boeve LMS, Hulshof M, Vis AN, Zwinderman AH, Twisk JWR, Witjes WPJ, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial. Eur Urol. 2019;75(3):410\u20138.","journal-title":"Eur Urol"},{"issue":"1","key":"4961_CR8","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.eururo.2024.03.018","volume":"86","author":"S Roy","year":"2024","unstructured":"Roy S, Fervaha G, Spratt DE, Sun Y, Kishan AU, Loblaw A, et al. Prostate Radiotherapy in Low-volume Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis. Eur Urol. 2024;86(1):10\u20137.","journal-title":"Eur Urol"},{"issue":"10467","key":"4961_CR9","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/S0140-6736(24)01865-8","volume":"404","author":"A Bossi","year":"2024","unstructured":"Bossi A, Foulon S, Maldonado X, Sargos P, MacDermott R, Kelly P, et al. Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 x 2 factorial design. Lancet. 2024;404(10467):2065\u201376.","journal-title":"Lancet"},{"issue":"5","key":"4961_CR10","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.euo.2022.06.001","volume":"5","author":"B Dai","year":"2022","unstructured":"Dai B, Zhang S, Wan FN, Wang HK, Zhang JY, Wang QF, et al. Combination of Androgen Deprivation Therapy with Radical Local Therapy Versus Androgen Deprivation Therapy Alone for Newly Diagnosed Oligometastatic Prostate Cancer: A Phase II Randomized Controlled Trial. Eur Urol Oncol. 2022;5(5):519\u201325.","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"4961_CR11","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/bju.15669","volume":"130","author":"P Sooriakumaran","year":"2022","unstructured":"Sooriakumaran P, Wilson C, Rombach I, Hassanali N, Aning J, A, DL, et al. Feasibility and safety of radical prostatectomy for oligo-metastatic prostate cancer: the Testing Radical prostatectomy in men with prostate cancer and oligo-Metastases to the bone (TRoMbone) trial. BJU Int. 2022;130(1):43\u201353.","journal-title":"BJU Int"},{"key":"4961_CR12","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.euros.2021.05.006","volume":"29","author":"N Lumen","year":"2021","unstructured":"Lumen N, De Bleser E, Buelens S, Verla W, Poelaert F, Claeys W, et al. The Role of Cytoreductive Radical Prostatectomy in the Treatment of Newly Diagnosed Low-volume Metastatic Prostate Cancer. Results from the Local Treatment of Metastatic Prostate Cancer (LoMP) Registry. Eur Urol Open Sci. 2021;29:68\u201376.","journal-title":"Eur Urol Open Sci"},{"issue":"6","key":"4961_CR13","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/bju.15553","volume":"129","author":"S Buelens","year":"2022","unstructured":"Buelens S, Poelaert F, Claeys T, De Bleser E, Dhondt B, Verla W, et al. Multicentre, prospective study on local treatment of metastatic prostate cancer (LoMP study). BJU Int. 2022;129(6):699\u2013707.","journal-title":"BJU Int"},{"key":"4961_CR14","doi-asserted-by":"publisher","unstructured":"Graefen M, Falkenbach F, Maurer T, Budaus L, Tilki D, Karakiewicz PI et al. Best Systemic Therapy With or Without Radical Prostatectomy in the Management of Men With Oligometastatic Prostate Cancer: The RAMPP Randomised Controlled Trial. Eur Urol. 2025. https:\/\/doi.org\/10.1016\/j.eururo.2025.09.4144","DOI":"10.1016\/j.eururo.2025.09.4144"},{"issue":"6","key":"4961_CR15","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.euf.2024.05.023","volume":"10","author":"C Shen","year":"2024","unstructured":"Shen C, Yan W, Chen S, Xu W, Wang X, Dong J, et al. Robot-assisted Radical Prostatectomy with the KangDuo Surgical System Versus the da Vinci Si System: A Prospective, Double-center, Randomized Controlled Trial. Eur Urol Focus. 2024;10(6):1019\u201326.","journal-title":"Eur Urol Focus"},{"issue":"1","key":"4961_CR16","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41391-019-0164-z","volume":"23","author":"C Huang","year":"2020","unstructured":"Huang C, Song G, Wang H, Lin Z, Wang H, Ji G, et al. Preoperative PI-RADS Version 2 scores helps improve accuracy of clinical nomograms for predicting pelvic lymph node metastasis at radical prostatectomy. Prostate Cancer Prostatic Dis. 2020;23(1):116\u201326.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"8","key":"4961_CR17","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med. 2015;373(8):737\u201346.","journal-title":"N Engl J Med"},{"issue":"25","key":"4961_CR18","doi-asserted-by":"publisher","first-page":"4065","DOI":"10.1200\/JCO.22.02765","volume":"41","author":"RE Bristow","year":"2023","unstructured":"Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis. J Clin Oncol. 2023;41(25):4065\u201376.","journal-title":"J Clin Oncol"},{"issue":"23","key":"4961_CR19","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1200\/JCO.18.01688","volume":"37","author":"PE Bonnot","year":"2019","unstructured":"Bonnot PE, Piessen G, Kepenekian V, Decullier E, Pocard M, Meunier B, et al. Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer With Peritoneal Metastases (CYTO-CHIP study): A Propensity Score Analysis. J Clin Oncol. 2019;37(23):2028\u201340.","journal-title":"J Clin Oncol"},{"issue":"1","key":"4961_CR20","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.eururo.2023.09.016","volume":"85","author":"MO Grimm","year":"2024","unstructured":"Grimm MO, Oya M, Choueiri TK, Motzer RJ, Schmidinger M, Quinn DI, et al. Impact of Prior Cytoreductive Nephrectomy on Efficacy in Patients with Synchronous Metastatic Renal Cell Carcinoma Treated with Avelumab plus Axitinib or Sunitinib: Post Hoc Analysis from the JAVELIN Renal 101 Phase 3 Trial. Eur Urol. 2024;85(1):8\u201312.","journal-title":"Eur Urol"},{"issue":"3","key":"4961_CR21","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/s41571-019-0284-3","volume":"17","author":"MJ Connor","year":"2020","unstructured":"Connor MJ, Shah TT, Horan G, Bevan CL, Winkler M, Ahmed HU. Cytoreductive treatment strategies for de novo metastatic prostate cancer. Nat Rev Clin Oncol. 2020;17(3):168\u201382.","journal-title":"Nat Rev Clin Oncol"},{"issue":"23","key":"4961_CR22","doi-asserted-by":"publisher","first-page":"11089","DOI":"10.1158\/0008-5472.CAN-06-2407","volume":"66","author":"RN Kaplan","year":"2006","unstructured":"Kaplan RN, Rafii S, Lyden D. Preparing the soil: the premetastatic niche. Cancer Res. 2006;66(23):11089\u201393.","journal-title":"Cancer Res"},{"issue":"8","key":"4961_CR23","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.tig.2018.05.007","volume":"34","author":"KL Pogrebniak","year":"2018","unstructured":"Pogrebniak KL, Curtis C. Harnessing Tumor Evolution to Circumvent Resistance. Trends Genet. 2018;34(8):639\u201351.","journal-title":"Trends Genet"},{"issue":"6","key":"4961_CR24","doi-asserted-by":"publisher","first-page":"100597","DOI":"10.1016\/j.esmoop.2022.100597","volume":"7","author":"M von Deimling","year":"2022","unstructured":"von Deimling M, Rajwa P, Tilki D, Heidenreich A, Pallauf M, Bianchi A, et al. The current role of precision surgery in oligometastatic prostate cancer. ESMO Open. 2022;7(6):100597.","journal-title":"ESMO Open"},{"issue":"3","key":"4961_CR25","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.eururo.2014.04.009","volume":"66","author":"C Gratzke","year":"2014","unstructured":"Gratzke C, Engel J, Stief CG. Role of radical prostatectomy in metastatic prostate cancer: data from the Munich Cancer Registry. Eur Urol. 2014;66(3):602\u20133.","journal-title":"Eur Urol"},{"issue":"3","key":"4961_CR26","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.juro.2014.09.089","volume":"193","author":"A Heidenreich","year":"2015","unstructured":"Heidenreich A, Pfister D, Porres D. Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study. J Urol. 2015;193(3):832\u20138.","journal-title":"J Urol"},{"issue":"6","key":"4961_CR27","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/j.eururo.2013.11.012","volume":"65","author":"SH Culp","year":"2014","unstructured":"Culp SH, Schellhammer PF, Williams MB. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. Eur Urol. 2014;65(6):1058\u201366.","journal-title":"Eur Urol"},{"issue":"4","key":"4961_CR28","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.euf.2023.01.011","volume":"9","author":"P Rajwa","year":"2023","unstructured":"Rajwa P, Zattoni F, Maggi M, Marra G, Kroyer P, Shariat SF, et al. Cytoreductive Radical Prostatectomy for Metastatic Hormone-sensitive Prostate Cancer-Evidence from Recent Prospective Reports. Eur Urol Focus. 2023;9(4):637\u201341.","journal-title":"Eur Urol Focus"},{"issue":"1","key":"4961_CR29","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.eururo.2017.03.020","volume":"72","author":"SR Leyh-Bannurah","year":"2017","unstructured":"Leyh-Bannurah SR, Gazdovich S, Budaus L, Zaffuto E, Briganti A, Abdollah F, et al. Local Therapy Improves Survival in Metastatic Prostate Cancer. Eur Urol. 2017;72(1):118\u201324.","journal-title":"Eur Urol"},{"issue":"7","key":"4961_CR30","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/nrurol.2017.72","volume":"14","author":"F Saad","year":"2017","unstructured":"Saad F. Prostate cancer: \u2018The prostate\u2019 in patients with metastatic prostate cancer: to treat or not to treat? Nat Rev Urol. 2017;14(7):398\u20139.","journal-title":"Nat Rev Urol"},{"issue":"2","key":"4961_CR31","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","volume":"86","author":"D Tilki","year":"2024","unstructured":"Tilki D, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer. Eur Urol. 2024;86(2):164\u201382.","journal-title":"Eur Urol"},{"issue":"2","key":"4961_CR32","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.eururo.2018.03.030","volume":"74","author":"S Han","year":"2018","unstructured":"Han S, Woo S, Kim YJ, Suh CH. Impact of (68)Ga-PSMA PET on the Management of Patients with Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. 2018;74(2):179\u201390.","journal-title":"Eur Urol"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-026-04961-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-04961-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-04961-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:02:43Z","timestamp":1791309763000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12916-026-04961-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,30]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4961"],"URL":"https:\/\/doi.org\/10.1186\/s12916-026-04961-2","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,30]]},"assertion":[{"value":"24 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the ethics committees of Peking University First Hospital (2018-R-177), the Second Affiliated Hospital of Tianjin Medical University (KY2019K002), and Beijing Friendship Hospital (2018-030). Written informed consent was obtained from all participants.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"538"}}